Bristol-Myers: raises 2019 EPS targets
(CercleFinance.com) - On publishing Q3 results that beat expectations, Bristol-Myers Squibb said that it is now looking for adjusted EPS of 4.
25 dollars to 4.35 dollars in 2019, above a previous target range of 4.20 dollars to 4.30 dollars.
In Q3 2019, the pharmaceutical company posted adjusted EPS that is up 7% at 1.17 dollar, i.e. ten cents above the consensus.
Revenues increased by 6% to 6 billion dollars over the period (+7% excluding currency effects), with growth mainly boosted by its flagship products Eliquis (+22%), Orencia and Sprycel (+14% each).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
25 dollars to 4.35 dollars in 2019, above a previous target range of 4.20 dollars to 4.30 dollars.
In Q3 2019, the pharmaceutical company posted adjusted EPS that is up 7% at 1.17 dollar, i.e. ten cents above the consensus.
Revenues increased by 6% to 6 billion dollars over the period (+7% excluding currency effects), with growth mainly boosted by its flagship products Eliquis (+22%), Orencia and Sprycel (+14% each).
Copyright (c) 2019 CercleFinance.com. All rights reserved.